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Background: NADH dehydrogenase subunit-2 237 leucine/methionine (ND2-237 Leu/Met) polymorphism
reportedly influences the effects of cigarette smoking on respiratory function, risk of dyslipidemia, serum
non-high-density lipoprotein cholesterol levels, hematological parameters and intraocular pressure. The objective
of this study was to investigate whether ND2-237 Leu/Met polymorphism modifies the effects of cigarette smoking
on serum liver enzyme levels in male Japanese health check-up examinees.
Methods: A total of 421 male subjects (mean age ± SD, 54.1 ± 7.7 years) were selected from among individuals
visiting the hospital for regular medical check-ups. After ND2-237 Leu/Met genotyping, a cross-sectional study
assessing the combined effects of ND2-237 Leu/Met polymorphism and cigarette smoking on serum aspartate
aminotransferase levels, serum alanine aminotransferase (ALT) levels and serum gamma-glutamyltransferase (GGT)
levels was then conducted.
Results: No statistically significant differences in serum liver enzyme levels among the three smoking status groups
(never- or ex-smokers, 1–20 cigarettes smoked per day and >20 cigarettes smoked per day) by ND2-237 Leu/Met
genotype were observed. However, for men with ND2-237Met, cigarette smoking significantly increased the risk of
elevated levels of serum ALT (>30 U/L) or serum GGT (≥60 U/L or >51 U/L) (P for trend = 0.031, P for trend = 0.007
and P for trend = 0.004, respectively). After adjustment for age, body mass index, alcohol consumption, coffee
consumption, antihypertensive treatment and antidiabetic treatment, a significant association between cigarette
smoking and risk of elevated levels of serum ALT (>30 U/L) or serum GGT (≥60 U/L or >51 U/L) was also
observed (P for trend = 0.032, P for trend = 0.019 and P for trend = 0.009, respectively). Surprisingly, for men
with ND2-237Leu, cigarette smoking significantly decreased the risk of elevated levels of serum ALT (>30 U/L
or ≥25 U/L) (P for trend = 0.026 and P for trend = 0.003, respectively).
Conclusions: Cigarette smoking appears to increase the risk of elevated levels of serum ALT or serum GGT in
ND2-237Met genotypic men, but to decrease the risk of elevated levels of serum ALT in ND2-237Leu genotypic men.
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Hepatologists have not considered cigarette smoking to be
a causative agent for chronic liver diseases [1]. However,
cigarette smoking induces direct or indirect toxic effects,
immunological effects and oncogenic effects on the liver
[2]. There is increasing evidence that cigarette smoking
deleteriously influences the incidence, severity or clinical
course of many types of chronic liver disease [1]. Several
epidemiological surveys [3-7] have reported that cigarette
smoking is positively associated with serum liver enzyme
levels, which have been clinically used as a biomarker for
liver disease.
Mitochondrial DNA cytosine/adenine (Mt5178 C/A)
polymorphism, also known as NADH dehydrogenase
subunit-2 237 leucine/methionine (ND2-237 Leu/Met)
polymorphism, is associated with longevity in the Japa-
nese population [8]. The frequency of the ND2-237Met
genotype is significantly higher in Japanese centenarians
than in the general population [8]. Japanese individuals
with ND2-237Met are more resistant to lifestyle-related
adult-onset diseases, such as hypertension [9], diabetes
[10], myocardial infarction [11,12] and cerebrovascular
disorders [13], than those with ND2-237Leu. Moreover,
ND2-237 Leu/Met polymorphism modulates the effects
of cigarette smoking on respiratory function [14], the
risk of dyslipidemia [15], serum non-high-density lipo-
protein (non-HDL) cholesterol levels [16], hematological
parameters [17] and intraocular pressure [18]. However,
there has been no research on the interactive effects of
ND2-237 Leu/Met polymorphism and cigarette smoking
on serum liver enzyme levels; specifically, serum aspartate
aminotransferase (AST) levels, serum alanine aminotrans-
ferase (ALT) levels or serum gamma-glutamyltransferase
(GGT) levels.
The objective of this study is to investigate whether
there is a joint effect of ND2-237 Leu/Met polymorph-
ism and habitual smoking on serum liver enzyme levels
in male Japanese health check-up examinees.
Subjects and methods
Subjects
Participants were recruited from among individuals visit-
ing the Mito Red Cross Hospital for regular medical
check-ups between August 1999 and August 2000. This
study was conducted in accordance with the Declaration
of Helsinki and was approved by the Ethics Committee
of the Kyorin University School of Medicine. Written in-
formed consent was obtained from 602 volunteers before
participation. Because the number of women was insuffi-
cient for classification into groups based on ND2-237
Leu/Met genotype and cigarette smoking, female health
check-up examinees were excluded. Male health check-
up examinees with unclear data were also excluded.
Thus, 442 men were enrolled in the study. Twenty-oneindividuals with a history of chronic liver diseases, in-
cluding hepatitis B and hepatitis C, were also excluded.
Therefore, subjects comprised 421 Japanese men (age,
54.1 ± 7.7 years; mean ± SD).
Clinical characteristics of subjects
Blood chemical and physical data, including serum AST
levels, serum ALT levels and serum GGT levels, in the
present study were obtained from the results of regular
medical check-ups [19]. Elevated levels of serum AST
were defined as ≥30 U/L [20]. Elevated levels of serum
ALT were defined as >30 U/L [21], or defined as ≥25 U/L
[22]. Elevated levels of serum GGT were defined as ≥60
U/L [4-6] or >51 U/L [23,24]. Body mass index (BMI) was
defined as the ratio of subject weight (kg) to the square of
subject height (m). A survey of habitual smoking, alcohol
consumption and coffee intake was performed by means
of self-reported questionnaire. Smoking status was classi-
fied based on the number of cigarettes smoked per day
(never- or ex-smokers; 1–20 cigarettes smoked per day;
and >20 cigarettes smoked per day). Alcohol consumption
was classified based on drinking frequency (non- or ex-
drinkers; occasional drinkers, which include those who
drink several times per week or per month; and daily
drinkers). Coffee consumption was categorized based on
the number of cups of coffee per day (less than one cup
per day; one or two cups per day; and more than three
cups per day). Information on antihypertensive treatment
or antidiabetic treatment was derived from health check-
up records.
Genotyping
DNA was extracted from white blood cells using the
DNA Extractor WB kit (Wako Pure Chemical Industries,
Osaka, Japan). ND2-237 Leu/Met polymorphism was de-
tected by polymerase chain reaction (PCR) and digestion
with AluI restriction enzyme. Primer sequences were: for-
ward 5′-CTTAGCATACTCCTCAATTACCC-3′; and re-
verse 5′-GTGAATTCTTCGATAATGGCCCA-3′. PCR
was performed with 50 ng of genomic DNA in buffer con-
taining 0.2 μmol/l each primer, 1.25 mmol/l dNTPs,
1.5 mmol/l MgCl2 and 1 U of Taq DNA polymerase. After
initial denaturation at 94°C for 5 min, PCR was conducted
through 40 cycles in the following steps: denaturation at
94°C for 30 s, annealing at 60°C for 60 s and polymerase
extension at 72°C for 90 s. After cycling, a final extension
at 72°C for 10 min was performed. PCR products were
digested with AluI restriction enzyme (Nippon Gene,
Tokyo, Japan) at 37°C overnight, and were electropho-
resed on 1.5% agarose gels stained with ethidium bromide
for visualization under ultraviolet light. The absence of an
AluI site was designated as Mt5178A (ND2-237Met), and
the presence of this restriction site was designated as
Mt5178C (ND2-237Leu).
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Statistical analyses were performed using SAS statistical
software version 9.3 for Windows. Multiple logistic re-
gression analysis was used to calculate odds ratios (ORs)
for the risk of elevated levels of serum liver enzymes
(AST: ≥30 U/L; ALT: >30 U/L or ≥25 U/L; GGT: ≥60 U/L
or >51 U/L). For multiple logistic regression analysis and
analysis of covariance, alcohol consumption (non- or ex-
drinkers = 0, occasional drinkers, including those who
drink several times per week or per month = 1, daily
drinkers = 2), coffee consumption (<1 cup per day = 1, 1–2
cups per day = 2, ≥3 cups per day = 3), antihypertensive
treatment (subjects without antihypertensive treat-
ment = 0, those under antihypertensive treatment = 1)




Elevated levels of serum AST (≥30 U/L) (%)****
ALT (U/L)***
Elevated levels of serum ALT (>30 U/L) (%)****
Elevated levels of serum ALT (≥25 U/L) (%)****
GGT (U/L) ***
Elevated levels of serum GGT (≥60 U/L) (%)****








Smoking status (never- or ex-/1–20 cigarettes per day/>20 cigarettes per day
Alcohol consumption (non- or ex-/occasionally/daily) (%)****
Coffee consumption (<1 cup per day/1-2cups per day/≥3 cups per day) (%)*
Subjects under antihypertensive treatment (%)****
Subjects under antidiabetic treatment (%)****
Smoking duration (y)*
BMI; body mass index, AST; aspartate aminotransferase, ALT; alanine aminotransfera
diastolic blood pressure, T-C; total cholesterol, LDL-C; low-density lipoprotein choles
plasma glucose.
Age, BMI, SBP, DBP, T-C levels, LDL-C levels, HDL-C levels and smoking duration are
levels are given as median (interquartile range). *Student’s t-test, **Welch’s t-test, **
differences between ND2-237Leu and ND2-237Met.treatment = 0, those under antidiabetic treatment = 1)
were numerically coded. Differences with P values of less
than 0.05 were considered to be statistically significant.
Results
No significant differences in clinical characteristics, in-
cluding serum liver enzyme levels, were observed be-
tween the ND2-237Leu and ND2-237Met genotypes
(Table 1). For either definition of elevated levels of serum
liver enzymes (AST: ≥30 U/L; ALT: >30 U/L or ≥25 U/L;
GGT: ≥60 U/L or >51 U/L), no significant differences in
the frequency of subjects with elevated levels of serum
liver enzymes were observed between men with ND2-
237Leu and those with ND2-237Met. Frequency of smok-
ing status (never- or ex-smokers; 1–20 cigarettes smokedLeu/Met genotype
ND2-237Leu ND2-237Met P value
N = 251 N = 170
54.5 (7.6) 53.6 (7.8) 0.245
23.1 (2.8) 23.5 (2.6) 0.103
22 (18–27) 23 (19–27) 0.687
18.7 18.2 0.899
21 (15–32) 24 (18–35) 0.471
27.1 30.6 0.436
37.9 45.9 0.100
42 (27–75) 47 (30–75) 0.427
34.7 38.8 0.384
39.4 45.9 0.189
126.1 (16.0) 125.7 (13.9) 0.614
73.9 (10.5) 73.5 (9.0) 0.628
204.2 (31.5) 202.5 (31.9) 0.590
122.5 (30.4) 118.4 (31.4) 0.182
55.0 (13.6) 55.9 (15.7) 0.576
112 (84–156) 113 (81–161) 0.378
97 (92–105) 97 (91–103) 0.240
) (%) 59.4/27.9/12.7 58.2/27.1/14.7 0.846
17.9/34.3/47.8 12.9/40.0/47.1 0.285







N = 102 N = 71
33.5 (8.5) 32.4 (7.3) 0.352
se, GGT; gamma-glutamyltransferase, SBP; systolic blood pressure, DBP;
terol, HDL-C; high-density lipoprotein cholesterol, TG; triglyceride, FPG; fasting
given as means (S.D.). GGT levels, AST levels, ALT levels, TG levels and FPG
*Mann–Whitney test, ****chi-squared test. All P values depict significance of
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nificantly different between the ND2-237Leu and ND2-
237Met genotypes. Smoking duration was not significantly
different between current smokers with ND2-237Leu and
those with ND2-237Met. The lowest of smoking dur-
ation was 5 years in ND2-237Leu genotypic current
smokers and was 9 years in ND2-237Met genotypic
current smokers.
Tukey-Kramer correction for multiple comparisons re-
vealed no statistically significant differences in serum
AST, ALT or GGT levels in the three smoking status
groups (never- or ex-smokers, 1–20 cigarettes smoked
per day and >20 cigarettes smoked per day) by ND2-237
Leu/Met genotype (Table 2). After adjusting for age,
BMI, alcohol consumption, coffee consumption, antihy-
pertensive treatment and antidiabetic treatment, no sig-
nificant relationships between cigarette consumption
and any serum liver enzyme levels were observed in ei-
ther ND2-237Leu or ND2-237Met genotypic men.
In the case of elevated levels of serum ALT, defined as
serum ALT levels > 30 U/L, for subjects with ND2-
237Leu, a negative and significant association between
cigarette consumption and risk of elevated levels of serum
ALT was observed (P for trend = 0.007) (Table 3). How-
ever, after adjusting for age, BMI, alcohol consumption,
coffee consumption, antihypertensive treatment and anti-
diabetic treatment, that association disappeared. In the
case of elevated levels of serum ALT, defined as serum
ALT levels ≥ 25 U/L, for subjects with ND2-237Leu, a
negative and significant association between cigaretteTable 2 Serum liver enzyme levels by smoking status and ND
Smoking
Never- or ex-smokers 1-20 cigarettes smoke
ND2-237Leu N = 149 N = 70
AST (U/L) 24.5 (3.9) 23.2 (5.6)
AST (U/L)† 20.4 (7.0) 18.4 (8.2)
ALT (U/L) 26.7 (3.2) 24.8 (4.6)
ALT (U/L)† 23.8 (5.6) 21.9 (6.6)
GGT (U/L) 65.4 (6.3) 67.8 (9.2)
GGT (U/L)† 55.6 (10.8) 61.9 (12.6)
ND2-237Met N = 99 N = 46
AST (U/L) 24.7 (1.3) 26.3 (2.0)
AST (U/L)† 19.9 (2.7) 24.0 (2.7)
ALT (U/L) 27.9 (2.3) 33.0 (3.4)
ALT (U/L)† 22.2 (4.6) 31.4 (4.7)
GGT (U/L) 56.4 (5.1) 70.4 (7.5)
GGT (U/L)† 46.9 (10.5) 64.1 (10.7)
AST; aspartate aminotransferase, ALT; alanine aminotransferase, GGT; gamma-glutam
†AST, †ALT and †GGT levels are given as least-square means (S.E) adjusted for age,
treatment and antidiabetic treatment.
Tukey-Kramer correction for multiple comparisons was applied.consumption and risk of elevated levels of serum ALT
was observed (P for trend = 0.003). The OR for elevated
levels of serum ALT was significantly lower in subjects
with ND2-237Leu who consumed >20 cigarettes per day
than in never- or ex-smokers with ND2-237Leu (OR =
0.282, 95% confidence interval (CI): 0.110-0.726, P =
0.009). After the aforementioned adjustment, the nega-
tive and significant association between cigarette con-
sumption and risk of elevated levels of serum ALT
remained significant (P for trend = 0.010). The adjusted
OR for elevated levels of serum ALT was significantly
lower in subjects with ND2-237Leu who consumed >20
cigarettes per day than in never- or ex-smokers with
ND2-237Leu (OR = 0.255, 95% CI: 0.084-0.776, P =
0.016). On the other hand, for subjects with ND2-
237Met, in the case of elevated levels of serum ALT,
defined as serum ALT levels > 30 U/L, the positive and
significant association between cigarette consumption
and risk of elevated levels of serum ALT was observed
(P for trend = 0.031). The OR for elevated levels of
serum ALT was significantly higher in subjects with
ND2-237Met who consumed >20 cigarettes per day than
in never- or ex-smokers with ND2-237Met (OR = 2.732,
95% CI: 1.104-6.762, P = 0.030). After the aforementioned
adjustment, the positive and significant association be-
tween cigarette consumption and risk of elevated levels
of serum ALT remained significant (P for trend =
0.032). The adjusted OR for elevated levels of serum
ALT was significantly higher in subjects with ND2-
237Met who consumed >20 cigarettes per day than in2-237 Leu/Met genotype
status P for trend
















body mass index, alcohol consumption, coffee consumption, antihypertensive
Table 3 Odds ratios (ORs) and 95% confidence intervals (CIs) for elevated levels of serum alanine aminotransferase
(ALT) by ND2-237 Leu/Met genotype and smoking status
Genotype and number of
cigarettes smoked daily
Frequency
OR (95% CI) Adjusted OR
† (95% CI)Normal levels of serum ALT Elevated levels of serum ALT
serum ALT levels ≤ 30 U/L serum ALT levels > 30 U/L
ND2-237Leu
0 (never- or ex-smoker) 101 (67.8) 48 (32.2) 1 (reference) 1 (reference)
1-20 55 (78.6) 15 (21.4) 0.574 (0.295-1.117) 0.525 (0.237-1.166)
>20 27 (84.4) 5 (15.6) 0.390 (0.141-1.074) 0.462 (0.143-1.492)
P for trend = 0.026 P for trend = 0.120
ND2-237Met
0 (never- or ex-smoker) 74 (74.8) 25 (25.2) 1 (reference) 1 (reference)
1-20 31 (67.4) 15 (32.6) 1.432 (0.660-3.079) 1.826 (0.723-4.614)
>20 13 (52.0) 12 (48.0) 2.732 (1.104-6.762)* 3.017 (1.064-8.560)*
P for trend = 0.031 P for trend = 0.032
serum ALT levels < 25 U/L serum ALT levels ≥ 25 U/L
ND2-237Leu
0 (never- or ex-smoker) 82 (55.0) 67 (45.0) 1 (reference) 1 (reference)
1-20 48 (68.6) 22 (31.4) 0.561 (0.308-1.021) 0.501 (0.248-1.010)
>20 26 (81.3) 6 (18.7) 0.282 (0.110-0.726)** 0.255 (0.084-0.776)*
P for trend = 0.003 P for trend = 0.010
ND2-237Met
0 (never- or ex-smoker) 54 (54.6) 45 (45.4) 1 (reference) 1 (reference)
1-20 28 (60.9) 18 (39.1) 0.771 (0.378-1.572) 0.828 (0.365-1.879)
>20 10 (40.0) 15 (60.0) 1.800 (0.737-4.395) 1.675 (0.633-4.435)
P for trend = 0.408 P for trend = 0.459
†OR adjusted for age, body mass index, habitual alcohol consumption, coffee consumption, antihypertensive treatment and antidiabetic treatment.
*P < 0.05, **P < 0.01.
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95% CI: 1.064-8.560, P = 0.038). The risk of elevated
levels of serum AST does not depend on cigarette con-
sumption for either ND2-237Leu genotypic subjects or
ND2-237Met genotypic subjects (data not shown).
In the case of elevated levels of serum GGT, defined as
serum GGT levels ≥ 60 U/L, for subjects with ND2-
237Met, the risk of elevated levels of serum GGT may
depend on cigarette consumption (P for trend = 0.007)
(Table 4). The OR for elevated levels of serum GGT was
significantly higher in subjects with ND2-237Met who
consumed >20 cigarettes per day than in never- or ex-
smokers with ND2-237Met (OR = 3.289, 95% CI: 1.330-
8.138, P = 0.010). After adjusting for age, BMI, alcohol
consumption, coffee consumption, antihypertensive treat-
ment and antidiabetic treatment, the risk of elevated levels
of serum GGT may also depend on cigarette consumption
(P for trend = 0.019). After the aforementioned adjustment,
the OR for elevated levels of serum GGT was significantly
higher in subjects with ND2-237Met who consumed >20
cigarettes per day than in never- or ex-smokers with ND2-237Met (adjusted OR = 3.030, 95% CI: 1.160-7.918, P =
0.024). In the case of elevated levels of serum GGT, defined
as serum GGT levels > 51 U/L, for subjects with ND2-
237Met, the risk of elevated levels of serum GGT may de-
pend on cigarette consumption (P for trend = 0.004). The
OR for elevated levels of serum GGT was significantly
higher in subjects with ND2-237Met who consumed >20
cigarettes per day than in never- or ex-smokers with ND2-
237Met (OR = 3.561, 95% CI: 1.400-9.058, P = 0.008). After
adjusting for age, BMI, alcohol consumption, coffee con-
sumption, antihypertensive treatment and antidiabetic
treatment, the risk of elevated levels of serum GGT may
also depend on cigarette consumption (P for trend =
0.009). After the aforementioned adjustment, the OR for
elevated levels of serum GGT was significantly higher in
subjects with ND2-237Met who consumed >20 cigarettes
per day than in never- or ex-smokers with ND2-237Met
(adjusted OR = 3.304, 95% CI: 1.220-8.946, P = 0.019). On
the other hand, the association between ND2-237Leu
genotype and risk of elevated levels of serum GGT does
not appear to depend on cigarette consumption.
Table 4 Odds ratios (ORs) and 95% confidence intervals (CIs) for elevated levels of serum gamma-glutamyltransferase
(GGT) by ND2-237 Leu/Met genotype and smoking status
Genotype and number of
cigarettes smoked daily
Frequency
OR (95% CI) Adjusted OR
† (95% CI)Normal levels of serum GGT Elevated levels of serum GGT
serum GGT levels < 60 U/L serum GGT levels ≥ 60 U/L
ND2-237Leu
0 (never- or ex-smoker) 96 (64.4) 53 (35.6) 1 (reference) 1 (reference)
1-20 46 (65.7) 24 (34.3) 0.945 (0.520-1.717) 1.142 (0.570-2.291)
>20 22 (68.7) 10 (31.3) 0.823 (0.363-1.868) 1.133 (0.406-3.158)
P for trend = 0.648 P for trend = 0.772
ND2-237Met
0 (never- or ex-smoker) 68 (68.7) 31 (31.3) 1 (reference) 1 (reference)
1-20 26 (56.5) 20 (43.5) 1.687 (0.820-3.471) 1.926 (0.852-4.351)
>20 10 (40.0) 15 (60.0) 3.289 (1.330-8.138)* 3.030 (1.160-7.918)*
P for trend = 0.007 P for trend = 0.019
serum GGT levels ≤ 51 U/L serum GGT levels > 51 U/L
ND2-237Leu
0 (never- or ex-smoker) 87 (58.4) 62 (41.6) 1 (reference) 1 (reference)
1-20 43 (61.4) 27 (38.6) 0.881 (0.493-1.575) 1.128 (0.556-2.285)
>20 22 (68.7) 10 (31.3) 0.638 (0.282-1.442) 0.823 (0.297-2.280)
P for trend = 0.288 P for trend = 0.855
ND2-237Met
0 (never- or ex-smoker) 62 (62.6) 37 (37.4) 1 (reference) 1 (reference)
1-20 22 (47.8) 24 (52.2) 1.828 (0.901-3.709) 2.223 (0.994-4.969)
>20 8 (32.0) 17 (68.0) 3.561 (1.400-9.058)** 3.304 (1.220-8.946)*
P for trend = 0.004 P for trend = 0.009
†OR adjusted for age, body mass index, habitual alcohol consumption, coffee consumption, antihypertensive treatment and antidiabetic treatment.
*P < 0.05, **P < 0.01.
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In the present study, the combined effects of ND2-237
Leu/Met polymorphism and habitual smoking on the risk
of elevated levels of serum ALT or GGT were observed in
male Japanese health check-up examinees. To the best of
our knowledge, this is a novel gene-environment inter-
action on elevated levels of serum ALT or GGT. For
subjects with ND2-237Met, cigarette consumption may
increase the risk of raised levels of serum ALT or GGT.
On the other hand, for those with ND2-237Leu, cigarette
smoking appears to decrease the risk of elevated levels of
serum ALT.
Epidemiological approaches revealed that cigarette smok-
ing raises serum GGT levels [7] and is positively associated
with raised levels of serum ALT [3] or serum GGT [4-6].
However, genetic factors were not included as confounding
factors or effect modifiers in either of the aforementioned
studies. Contemplating the results of the present study, the
inclusion of genetic information may contribute to future
epidemiological surveys with regard to the effects of
cigarette consumption on serum ALT or GGT levels or
the risk of elevated levels of serum ALT or GGT.A large-scale population-based prospective study
found that elevated levels of serum ALT (>30 U/L in
men and >19 U/L in women) are associated with liver
disease mortality, and that elevated levels of serum GGT
(>51 U/L in men and >33 U/L in women) are associated
with not only liver disease mortality but also mortality
from all causes, malignancy and diabetes [23]. Another
large-scale prospective study showed that serum ALT
and GGT activity predicts future development of meta-
bolic syndrome [25]. A cross-sectional study showed the
association between serum GGT activity and metabolic
risk factors for cardiovascular disease (CVD) among
male Japanese subjects [26]. Therefore, based on the
prevention of not only liver damage but also metabolic
syndrome or CVD, smoking cessation should be encour-
aged, particularly for ND2-237Met genotypic men.
Among ND2-237Met genotypic men, cigarette con-
sumption may increase the risk of raised levels of serum
ALT or serum GGT. Except for respiratory function [14],
the effects of cigarette smoking on clinical or subclinical
findings are more apparent in men with ND2-237Met than
in those with ND2-237Leu [15-18]. Cigarette smoking
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(LDL) cholesterolemia or that of hypertriglyceridemia in
men with ND2-237Met [15]. Moreover, habitual smok-
ing also increases serum non-HDL cholesterol levels in
ND2-237Met genotypic men [16]. Considering our results
together with hyper-LDL cholesterolemia, hypertriglyc-
eridemia and high levels of non-HDL cholesterol as risk
factors for atherosclerotic diseases [27], habitual smoking
may offset the antiatherogenic properties of ND2-237Met
genotype. Among ND2-237Leu genotypic men, although
cigarette consumption appears to reduce the risk of raised
levels of serum ALT, it increases the risk of chronic ob-
structive pulmonary disease [14]. Therefore, smoking ces-
sation is also recommended for them.
The mechanisms of the joint effects of ND2-237 Leu/
Met polymorphism and habitual smoking on the ele-
vated levels of serum ALT or GGT presumably depend
on the biochemical differences in response to some
compounds in cigarette smoke between ND2-237Leu
and ND2-237Met. NADH dehydrogenase is regarded as
the major physiological site of reactive oxygen species
(ROS) generation in mitochondria, and is itself a target
of assault by ROS [28]. Extrapolation from animal
models [29,30] to human subjects would suggest that
ND2-237Met suppresses ROS production and/or pro-
tects NADH dehydrogenase itself from ROS. Cigarette
smoke contains high concentrations of ROS, and is
thought to activate endogenous sources of ROS [31].
Considering that serum GGT has potential as an early and
sensitive biomarker of oxidative stress [32], cigarette
smoking unexpectedly increases the risk of elevated levels
of serum GGT in ND2-237Met genotypic men rather than
in ND2-237Leu genotypic men. Surprisingly, habitual
smoking apparently decreases the risk of elevated levels of
serum ALT in men with ND2-237Leu. In any case, eluci-
dating these mechanisms remains a matter for further
pharmacological investigation.
Limited to the studies in which subjects were Japanese,
Interleukin-1β -31 T/C polymorphism [33] or cytochrome
P450 -3860 G/A polymorphism [34] influences the effects
of cigarette smoking on the risk of hepatocellular car-
cinoma. Moreover, gluthathione S-transferase polymor-
phisms, which are associated with risk of CVD and
diabetes, influence the effects of cigarette smoking on
the development of non-alcoholic fatty liver disease in
Japanese subjects [35]. Therefore, gene-gene or gene-
gene-environment interactions with liver diseases, in-
cluding elevated levels of serum ALT or GGT, should be
investigated. Moreover, we focused on only one single
nucleotide polymorphism (SNP) in a single gene, namely
Mt5178 C/A polymorphism in mitochondrial DNA. With
only a single SNP in a single gene, there is a very high
chance of false-positive or false-negative findings. There-
fore, utilization of an effective tool for sensitive andaccurate SNP detection, for example an SNP detector
[36], will be desirable for further molecular epidemio-
logical research.
In addition to the lack of other genetic information,
there are several crucial limitations in this study. First,
as compared with other epidemiological surveys on the
effects of cigarette smoking on serum liver enzyme levels
[3-6], the sample size was very small. Second, we ana-
lyzed only a single population, and to avoid errors in
molecular epidemiological survey, it is necessary to
analyze two or more independent data sets. Third, al-
though similar subject selections have been applied in
our previous studies [9,14-19,37], selection bias cannot
be ruled out. Fourth, as this was a cross-sectional study,
and it can indicate causal links, it cannot establish valid
causality. To overcome these limitations, a follow-up
study with a larger study sample, including additional pop-
ulations, is necessary. Fifth, we do not have any informa-
tion on the last cigarette smoked prior to the blood
sample collection; such information would be useful in
interpreting the present results. Sixth, because of a lack of
data on amounts of alcohol intake, the evaluation of habit-
ual alcohol intake was based on the frequency of alcohol
consumption. Alcohol consumption was considered to be
a confounding factor in the statistical analysis of this
study. Although we have also used this evaluation method
in previous studies [9,16,37], the existence of joint effects
between ND2-237 Leu/Met polymorphism and volume of
alcohol intake on serum ALT or GGT levels warrants fur-
ther investigation.
Conclusion
The present molecular epidemiological study demonstrates
that ND2-237 Leu/Met polymorphism modifies the effects
of cigarette smoking on the risk of elevated levels of serum
ALT or GGT in male Japanese health check-up examinees.
Cigarette consumption may increase the risk of elevated
levels of serum ALT or GGT in ND2-237Met genotypic
men. Surprisingly, habitual smoking appears to lower the
risk of elevated levels of serum ALT in ND2-237Leu geno-
typic men. This gene-environment interaction may help
elucidate the pathophysiological mechanisms underlying
the association between cigarette smoking and serum ALT
or GGT levels.
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